Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Large Growth in Short Interest

Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a significant increase in short interest in February. As of February 28th, there was short interest totalling 8,400 shares, an increase of 29.2% from the February 13th total of 6,500 shares. Approximately 0.7% of the company’s stock are short sold. Based on an average trading volume of 8,800 shares, the days-to-cover ratio is presently 1.0 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a report on Thursday, December 5th.

Xenetic Biosciences Trading Up 4.9 %

Shares of NASDAQ:XBIO opened at $3.67 on Tuesday. Xenetic Biosciences has a twelve month low of $2.78 and a twelve month high of $5.20. The company’s 50 day moving average is $4.03 and its 200 day moving average is $4.01. The company has a market cap of $5.66 million, a PE ratio of -1.38 and a beta of 2.17.

Hedge Funds Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. LGT Group Foundation purchased a new position in Xenetic Biosciences Inc (NASDAQ:XBIO) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned 0.71% of Xenetic Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.